School project · Delayed data · Not financial adviceTerms
SingularityViewAll companies

Stock research

Novo Nordisk A/S NVO

Healthcare · Drug Manufacturers - General

$38.64last close 2026-10-09 · market cap $170.57B · delayed data

Trailing returns

1M-13.29%
3M-19.94%
6M+4.52%
1Y-30.86%
5Y-11.91%

Basis: Adjusted daily closes.

What it does

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas.

Open NVO in the live terminal →

Valuation, cost of capital, SEC filings, ownership and more, with the source named on every figure.

Post on XLinkedInEmail

Where these figures come from

Delayed data. Not financial advice. Figures are read from the sources above at the dates shown; nothing here is a recommendation. Disclosures · All companies